{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:04:28Z","timestamp":1792785868954,"version":"4.5.0"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"AIRC","doi-asserted-by":"publisher","award":["IG 2021-25920"],"award-info":[{"award-number":["IG 2021-25920"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Progetti di Ricerca di Interesse Nazionale","award":["2022CZR88M"],"award-info":[{"award-number":["2022CZR88M"]}]},{"name":"Progetti di Ricerca di Interesse Nazionale","award":["P20227KXJK"],"award-info":[{"award-number":["P20227KXJK"]}]},{"name":"Ricerca Corrente Funds from the Italian Ministry of Health to Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico of Milan","id":[{"id":"https:\/\/ror.org\/0053ctp29","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background Adrenocortical carcinomas (ACC) are aggressive cancers with limited therapeutic options. Cyclin-dependent kinases (CDKs) 1\/2\/4 and polo-like kinase 1 (PLK1) are upregulated in ACC, suggesting their role as potential targets. Objective This study investigated the anti-tumour efficacy of the pan-CDK inhibitors (CDKi) dinaciclib, AT7519, and SNS-032; the CDK1-cyclin B1 inhibitor cucurbitacin E (curE); the PLK1 inhibitors (PLK1i) poloxin and plogosertib; and selected combination strategies in four genetically heterogeneous ACC cell lines (NCI-H295R, JIL-2266, MUC-1, and TVBF-7) and primary cultures. Results ACC cells showed marked CDK1\/2\/4 and PLK1 transcript and protein upregulation compared to normal adrenal gland. Dinaciclib reduced cell growth and induced apoptosis at low nanomolar doses. CurE induced weaker pro-apoptotic effects, whereas AT7519 and SNS-032 displayed activity only in JIL-2266 and MUC-1. Among PLK1i, plogosertib impaired proliferation and increased apoptosis in a nanomolar range. Dinaciclib-plogosertib combination produced the highest synergistic anti-proliferative effects in NCI-H295R and TVBF-7. In steroidogenic NCI-H295R cells, dinaciclib lowered cortisol secretion and downregulated CYP11A1, CYP17A1, CYP21A2, SF-1, and GR transcripts, as well as GR protein expression. In parallel, dinaciclib broadly suppressed CDK1\/2 axis and their downstream signalling proteins, including cyclin E1 and p21Waf1\/Cip1, consistent with G1\/S blockade. Plogosertib increased p-CDK1(Tyr15), cyclin B1, and \u03b3-H2AX levels, indicative of DNA damage and mitotic stress. Conclusions These results identify dinaciclib and plogosertib as the most effective inhibitors across all ACC models tested. Their simultaneous action on multiple checkpoints, alongside with their synergistic effect in selected cell lines, suggest a potential benefit of their use in ACC that needs to be further investigated in vivo.<\/jats:p>","DOI":"10.1093\/ejendo\/lvag155","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:46:18Z","timestamp":1786535178000},"page":"454-469","source":"Crossref","is-referenced-by-count":0,"title":["Pan-CDK and PLK1 inhibitors as a novel approach for targeted treatment of adrenocortical carcinomas"],"prefix":"10.1093","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9238-0367","authenticated-orcid":false,"given":"Emanuela","family":"Esposito","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan , Milan, 20122 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1573-036X","authenticated-orcid":false,"given":"Emma","family":"Nozza","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan , Milan, 20122 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan , Milan, 20122 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6977-5996","authenticated-orcid":false,"given":"Luca","family":"Bosoni","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan , Milan, 20122 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-1592","authenticated-orcid":false,"given":"Paul A","family":"Foster","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham , Birmingham, B15 2TT ,","place":["United Kingdom"]},{"name":"Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners , Birmingham, B15 2TT ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4906-8239","authenticated-orcid":false,"given":"Vasileios","family":"Chortis","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham , Birmingham, B15 2TT ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6260-3489","authenticated-orcid":false,"given":"Rosa","family":"Catalano","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan , Milan, 20122 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2218-9893","authenticated-orcid":false,"given":"Sonia","family":"Di Bari","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan , Milan, 20122 ,","place":["Italy"]},{"name":"PhD Programme in Experimental Medicine, University of Milan , Milan, 20122 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-8544","authenticated-orcid":false,"given":"Lucy","family":"Beevors","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham , Birmingham, B15 2TT ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-8906","authenticated-orcid":false,"given":"Guido","family":"Di Dalmazi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna, 40138 ,","place":["Italy"]},{"name":"Department of Medical and Surgical Sciences, Alma Mater University of Bologna , Bologna, 40126 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6315-4176","authenticated-orcid":false,"given":"Laura-Sophie","family":"Landwehr","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital W\u00fcrzburg, W\u00fcrzburg , 97080 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8906-2563","authenticated-orcid":false,"given":"Constanze","family":"Hantel","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH) , Zurich, 8091 ,","place":["Switzerland"]},{"name":"Medizinische Klinik und Poliklinik III, University Hospital Carl Gustav Carus Dresden , Dresden, 01304 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0835-0916","authenticated-orcid":false,"given":"Andrea","family":"Abate","sequence":"additional","affiliation":[{"name":"Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia , Brescia, 25121 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7827-0025","authenticated-orcid":false,"given":"Mariangela","family":"Tamburello","sequence":"additional","affiliation":[{"name":"Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia , Brescia, 25121 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1035-8551","authenticated-orcid":false,"given":"Alessandra","family":"Mangone","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan , Milan, 20122 ,","place":["Italy"]},{"name":"Endocrinology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico of Milan , Milan, 20122 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1137-461X","authenticated-orcid":false,"given":"Serena","family":"Palmieri","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico of Milan , Milan, 20122 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0556-7650","authenticated-orcid":false,"given":"Emanuele","family":"Ferrante","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico of Milan , Milan, 20122 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9065-3886","authenticated-orcid":false,"given":"Giovanna","family":"Mantovani","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan , Milan, 20122 ,","place":["Italy"]},{"name":"Endocrinology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico of Milan , Milan, 20122 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4424-7895","authenticated-orcid":false,"given":"Erika","family":"Peverelli","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan , Milan, 20122 ,","place":["Italy"]},{"name":"Endocrinology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico of Milan , Milan, 20122 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5020-2071","authenticated-orcid":false,"given":"Cristina L","family":"Ronchi","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham , Birmingham, B15 2TT ,","place":["United Kingdom"]},{"name":"Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners , Birmingham, B15 2TT ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"issue":"5","key":"2026093004231023100_lvag155-B1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S2213-8587(24)00378-4","article-title":"Adrenocortical carcinoma: a practical guide for clinicians","volume":"13","author":"Fassnacht","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"2026093004231023100_lvag155-B2","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1677\/erc.1.01025","article-title":"Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial","volume":"12","author":"Berruti","year":"2005","journal-title":"Endocr Relat Cancer"},{"issue":"23","key":"2026093004231023100_lvag155-B3","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"2026093004231023100_lvag155-B4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"Assi\u00e9","year":"2014","journal-title":"Nat Genet"},{"issue":"5","key":"2026093004231023100_lvag155-B5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","article-title":"Comprehensive pan-genomic characterization of adrenocortical carcinoma","volume":"29","author":"Zheng","year":"2016","journal-title":"Cancer Cell"},{"issue":"2","key":"2026093004231023100_lvag155-B6","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1158\/1078-0432.CCR-08-1067","article-title":"Molecular classification and prognostication of adrenocortical tumours by transcriptome profiling","volume":"15","author":"Giordano","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2026093004231023100_lvag155-B7","doi-asserted-by":"publisher","first-page":"E301","DOI":"10.1210\/jc.2011-1588","article-title":"Clinical and pathophysiological implications of chromosomal alterations in adrenocortical tumours: an integrated genomic approach","volume":"97","author":"Barreau","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026093004231023100_lvag155-B8","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.18632\/aging.101356","article-title":"A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas","volume":"9","author":"Hadjadj","year":"2017","journal-title":"Aging (Albany NY)"},{"issue":"68","key":"2026093004231023100_lvag155-B9","doi-asserted-by":"publisher","first-page":"33030","DOI":"10.18632\/oncotarget.26050","article-title":"Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response","volume":"9","author":"Nilubol","year":"2018","journal-title":"Oncotarget"},{"key":"2026093004231023100_lvag155-B10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3389\/fendo.2020.00219","article-title":"Targeted gene expression profile reveals CDK4 as therapeutic target for selected patients with adrenocortical carcinoma","volume":"11","author":"Liang","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2026093004231023100_lvag155-B11","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1186\/s12967-022-03641-y","article-title":"CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2\/M phase transition, and PANoptosis","volume":"20","author":"Ren","year":"2022","journal-title":"J Transl Med"},{"issue":"1","key":"2026093004231023100_lvag155-B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40169-015-0080-3","article-title":"Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma","volume":"5","author":"Bussey","year":"2016","journal-title":"Clin Transl Med"},{"issue":"1","key":"2026093004231023100_lvag155-B13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.surg.2018.04.080","article-title":"Over expression of DNA damage and cell cycle dependent proteins are associated with poor survival in patients with adrenocortical carcinoma","volume":"165","author":"Subramanian","year":"2019","journal-title":"Surgery"},{"issue":"1","key":"2026093004231023100_lvag155-B14","doi-asserted-by":"publisher","first-page":"e230403","DOI":"10.1530\/EC-23-0403","article-title":"PLK1 inhibitors as a new targeted treatment for adrenocortical carcinoma","volume":"13","author":"Warmington","year":"2023","journal-title":"Endocr Connect"},{"issue":"6","key":"2026093004231023100_lvag155-B15","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/ijc.35239","article-title":"Therapeutic potential of targeting the FLNA-regulated Wee1 kinase in adrenocortical carcinomas","volume":"156","author":"Esposito","year":"2025","journal-title":"Int J Cancer"},{"key":"2026093004231023100_lvag155-B16","doi-asserted-by":"publisher","first-page":"107997","DOI":"10.1016\/j.phrs.2025.107997","article-title":"Preclinical evaluation of the antitumoral efficacy of Wee1 inhibitor AZD1775 in adrenocortical carcinoma","volume":"221","author":"Nozza","year":"2025","journal-title":"Pharmacol Res"},{"issue":"2","key":"2026093004231023100_lvag155-B17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2026093004231023100_lvag155-B18","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1210\/endrev\/bnac012","article-title":"Update on biology and genomics of adrenocortical carcinomas: rationale for emerging therapies","volume":"43","author":"Lerario","year":"2022","journal-title":"Endocr Rev"},{"issue":"1","key":"2026093004231023100_lvag155-B19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12020-017-1270-0","article-title":"Palbociclib inhibits proliferation of human adrenocortical tumour cells","volume":"59","author":"Fiorentini","year":"2018","journal-title":"Endocrine"},{"issue":"2","key":"2026093004231023100_lvag155-B20","doi-asserted-by":"publisher","first-page":"bqab248","DOI":"10.1210\/endocr\/bqab248","article-title":"Ribociclib cytotoxicity alone or combined with progesterone and\/or mitotane in in vitro adrenocortical carcinoma cells","volume":"163","author":"Abate","year":"2022","journal-title":"Endocrinology"},{"issue":"1","key":"2026093004231023100_lvag155-B21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s13046-022-02464-5","article-title":"Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer","volume":"41","author":"Laha","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"2026093004231023100_lvag155-B22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.semcancer.2022.12.006","article-title":"CDK inhibitors from past to present: a new wave of cancer therapy","volume":"88","author":"Mughal","year":"2023","journal-title":"Semin Cancer Biol"},{"issue":"18","key":"2026093004231023100_lvag155-B23","doi-asserted-by":"publisher","first-page":"4776","DOI":"10.1158\/1078-0432.CCR-14-0325","article-title":"Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumours","volume":"20","author":"van der Biessen","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2026093004231023100_lvag155-B24","doi-asserted-by":"publisher","first-page":"1602752","DOI":"10.3389\/fimmu.2025.1602752","article-title":"PLK1 in cancer therapy: a comprehensive review of immunomodulatory mechanisms and therapeutic opportunities","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"issue":"10","key":"2026093004231023100_lvag155-B25","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1136\/gutjnl-2024-334274","article-title":"DNAJ-PKAc fusion heightens PLK1 inhibitor sensitivity in fibrolamellar carcinoma","volume":"74","author":"Chan","year":"2025","journal-title":"Gut"},{"issue":"13_Supplement","key":"2026093004231023100_lvag155-B26","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1158\/1538-7445.AM2017-4178","article-title":"Identification of pharmacodynamic markers, sensitive target indications and potential combinations","volume":"77","author":"Moureau","year":"2017","journal-title":"Proc Annu Meet Am Assoc Cancer Res"},{"issue":"8_Supplement_1","key":"2026093004231023100_lvag155-B27","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1158\/1538-7445.AM2025-5406","article-title":"Abstract 5406: evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker","volume":"85","author":"Jeong","year":"2025","journal-title":"Cancer Res"},{"issue":"8","key":"2026093004231023100_lvag155-B28","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","article-title":"Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor","volume":"9","author":"Parry","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"2026093004231023100_lvag155-B29","doi-asserted-by":"publisher","first-page":"598","DOI":"10.4161\/cbt.12.7.16475","article-title":"Cyclin-dependent kinase inhibitor dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models","volume":"12","author":"Feldmann","year":"2011","journal-title":"Cancer Biol Ther."},{"issue":"10","key":"2026093004231023100_lvag155-B30","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3390\/cancers11101433","article-title":"Potent activity of composite cyclin dependent kinase inhibition against hepatocellular carcinoma","volume":"11","author":"Shao","year":"2019","journal-title":"Cancers (Basel)."},{"issue":"1-2","key":"2026093004231023100_lvag155-B31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.mce.2003.12.020","article-title":"Adrenocortical cell lines","volume":"228","author":"Rainey","year":"2004","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"2026093004231023100_lvag155-B32","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1530\/EJE-20-1423","article-title":"A novel patient-derived cell line of adrenocortical carcinoma shows a pathogenic role of germline MUTYH mutation and high tumour mutational burden","volume":"184","author":"Landwehr","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"48","key":"2026093004231023100_lvag155-B33","doi-asserted-by":"publisher","first-page":"79292","DOI":"10.18632\/oncotarget.12685","article-title":"Targeting heterogeneity of adrenocortical carcinoma: evaluation and extension of preclinical tumour models to improve clinical translation","volume":"7","author":"Hantel","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"2026093004231023100_lvag155-B34","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.3390\/cells11091439","article-title":"A comprehensive investigation of steroidogenic signaling in classical and new experimental cell models of adrenocortical carcinoma","volume":"11","author":"Sigala","year":"2022","journal-title":"Cells"},{"issue":"3","key":"2026093004231023100_lvag155-B35","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3390\/endocrines5030019","article-title":"Human and murine cell lines for adrenocortical carcinoma and pheochromocytoma","volume":"5","author":"Luca","year":"2024","journal-title":"Endocrines"},{"key":"2026093004231023100_lvag155-B36","doi-asserted-by":"crossref","unstructured":"Zheng S, Wang W, Aldahdooh J, et al \u00a0SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets. Genomics Proteomics Bioinformatics. 2022;20(3):587\u2013596. 10.1016\/j.gpb.2022.01.004","DOI":"10.1016\/j.gpb.2022.01.004"},{"issue":"W1","key":"2026093004231023100_lvag155-B37","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"2026093004231023100_lvag155-B38","doi-asserted-by":"publisher","first-page":"dgaa616","DOI":"10.1210\/clinem\/dgaa616","article-title":"RNA sequencing and somatic mutation status of adrenocortical tumors: novel pathogenetic insights","volume":"105","author":"Di Dalmazi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026093004231023100_lvag155-B39","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3892\/ijmm.2022.5184","article-title":"CDK4\/6 inhibitor resistance mechanisms and treatment strategies (review)","volume":"50","author":"Huang","year":"2022","journal-title":"Int J Mol Med"},{"key":"2026093004231023100_lvag155-B40","doi-asserted-by":"publisher","first-page":"104324","DOI":"10.1016\/j.critrevonc.2024.104324","article-title":"Cyclin-dependent kinase 2 (CDK2) inhibitors and other novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions","volume":"196","author":"Gerosa","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026093004231023100_lvag155-B41","doi-asserted-by":"publisher","first-page":"116416","DOI":"10.1016\/j.ejmech.2024.116416","article-title":"Identification of naphthalimide-derivatives as novel PBD-targeted polo-like kinase 1 inhibitors with efficacy in drug-resistant lung cancer cells","volume":"271","author":"Li","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"9","key":"2026093004231023100_lvag155-B42","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.celrep.2016.10.077","article-title":"CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer","volume":"17","author":"Johnson","year":"2016","journal-title":"Cell Rep"},{"issue":"4","key":"2026093004231023100_lvag155-B43","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/1878-0261.13773","article-title":"The CDK12-BRCA1 signaling axis mediates dinaciclib-associated radiosensitivity through p53-mediated cellular senescence","volume":"19","author":"Flores","year":"2025","journal-title":"Mol Oncol"},{"issue":"5","key":"2026093004231023100_lvag155-B44","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41419-024-06724-4","article-title":"CDK9 inhibition as an effective therapy for small cell lung cancer","volume":"15","author":"Valdez Capuccino","year":"2024","journal-title":"Cell Death Dis"},{"issue":"3","key":"2026093004231023100_lvag155-B45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"16","key":"2026093004231023100_lvag155-B46","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.3390\/cancers13164200","article-title":"Novel insights into the molecular regulation of ribonucleotide reductase in adrenocortical carcinoma treatment","volume":"13","author":"Bothou","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"17","key":"2026093004231023100_lvag155-B47","doi-asserted-by":"publisher","first-page":"14926","DOI":"10.18632\/oncotarget.3717","article-title":"Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"issue":"10","key":"2026093004231023100_lvag155-B48","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1080\/15384101.2022.2041783","article-title":"Synthetic lethality of cyclin-dependent kinase inhibitor dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma","volume":"21","author":"Nelson","year":"2022","journal-title":"Cell Cycle"},{"key":"2026093004231023100_lvag155-B49","doi-asserted-by":"publisher","first-page":"150348","DOI":"10.1016\/j.bbrc.2024.150348","article-title":"Role of Wnt\/\u03b2-catenin pathway in cancer drug resistance: insights into molecular aspects of major solid tumors","volume":"729","author":"Samant","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"2026093004231023100_lvag155-B50","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/jmcb\/mjy072","article-title":"Mutant p53 in cancer therapy-the barrier or the path","volume":"11","author":"Zhou","year":"2019","journal-title":"J Mol Cell Biol"},{"issue":"3","key":"2026093004231023100_lvag155-B51","doi-asserted-by":"publisher","first-page":"e59588","DOI":"10.1371\/journal.pone.0059588","article-title":"The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling","volume":"8","author":"Desai","year":"2013","journal-title":"PLoS One"},{"key":"2026093004231023100_lvag155-B52","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673368870250602112835","article-title":"Advancements in CDK-based dual-target inhibitors for cancer therapy [published online ahead of print June 23, 2025]","author":"Dou","journal-title":"Curr Med Chem"},{"issue":"2","key":"2026093004231023100_lvag155-B53","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/1061186X.2020.1818760","article-title":"Polo-like kinase 1 as an emerging drug target: structure, function and therapeutic implications","volume":"29","author":"Shakeel","year":"2021","journal-title":"J Drug Target"},{"issue":"3","key":"2026093004231023100_lvag155-B54","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1158\/2767-9764.CRC-24-0085","article-title":"Activity of the ubiquitin-activating enzyme inhibitor TAK-243 in adrenocortical carcinoma cell lines, patient-derived organoids, and murine Xenografts","volume":"4","author":"Arakawa","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"5","key":"2026093004231023100_lvag155-B55","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3390\/cells13050368","article-title":"The CDK inhibitor dinaciclib improves cisplatin response in nonseminomatous testicular cancer: a preclinical study","volume":"13","author":"Rossini","year":"2024","journal-title":"Cells"},{"key":"2026093004231023100_lvag155-B56","doi-asserted-by":"publisher","first-page":"1014280","DOI":"10.3389\/fonc.2022.1014280","article-title":"Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer","volume":"12","author":"Howard","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"2026093004231023100_lvag155-B57","doi-asserted-by":"publisher","first-page":"43517","DOI":"10.1038\/srep43517","article-title":"WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance","volume":"7","author":"Zheng","year":"2017","journal-title":"Sci Rep"},{"issue":"11","key":"2026093004231023100_lvag155-B58","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.3390\/cells12111471","article-title":"Inhibiting WEE1 augments the antitumor efficacy of cisplatin in urothelial carcinoma by enhancing the DNA damage process","volume":"12","author":"Su","year":"2023","journal-title":"Cells"},{"issue":"1","key":"2026093004231023100_lvag155-B59","doi-asserted-by":"publisher","first-page":"5448","DOI":"10.1038\/s41598-025-34904-5","article-title":"Pharmacological WEE1 inhibition as a strategy to overcome cisplatin resistance in non-seminoma testicular cancer: insights from preclinical models","volume":"16","author":"Tamburello","year":"2026","journal-title":"Sci Rep"},{"key":"2026093004231023100_lvag155-B60","doi-asserted-by":"publisher","first-page":"678559","DOI":"10.3389\/fonc.2021.678559","article-title":"CDK9: a comprehensive review of its biology, and its role as a potential target for anti-cancer agents","volume":"11","author":"Anshabo","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"2026093004231023100_lvag155-B61","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1038\/s41467-017-01569-2","article-title":"Glucocorticoid-induced phosphorylation by CDK9 modulates the coactivator functions of transcriptional cofactor GRIP1 in macrophages","volume":"8","author":"Rollins","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"2026093004231023100_lvag155-B62","doi-asserted-by":"publisher","first-page":"9636","DOI":"10.1038\/s41598-018-27938-5","article-title":"DNA damage response induced by etoposide promotes steroidogenesis via GADD45A in cultured adrenal cells","volume":"8","author":"Tamamori-Adachi","year":"2018","journal-title":"Sci Rep"},{"issue":"11","key":"2026093004231023100_lvag155-B63","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1002\/j.1460-2075.1992.tb05493.x","article-title":"Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15","volume":"11","author":"Gu","year":"1992","journal-title":"EMBO J"},{"issue":"5","key":"2026093004231023100_lvag155-B64","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.3390\/ijms26052197","article-title":"Dinaciclib interrupts cell cycle and induces apoptosis in oral squamous cell carcinoma: mechanistic insights and therapeutic potential","volume":"26","author":"Oner","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2026093004231023100_lvag155-B65","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.cell.2008.05.043","article-title":"The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint","volume":"134","author":"Bassermann","year":"2008","journal-title":"Cell"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvag155\/70632528\/lvag155.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/195\/3\/454\/70632528\/lvag155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/195\/3\/454\/70632528\/lvag155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:23:19Z","timestamp":1790756599000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/195\/3\/454\/8760852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvag155","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,13]]}}}